There are 2137 resources available
LBA27 - Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
Presenter: Begona Perez Valderrama
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
704MO - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
Presenter: Petros Grivas
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
705MO - Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
Presenter: Pavlos Msaouel
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1814MO - Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: A randomized, open-label trial
Presenter: Atul Sharma
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1815MO - Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial
Presenter: Luigi Celio
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1816MO - ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey
Presenter: Teresa Smit
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1817MO - Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received granulocyte-colony stimulating factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC)
Presenter: Pietro Lapidari
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1818MO - Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? Intermediate results from the MeTHOS study
Presenter: Spyros Xynogalos
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
83MO - Co-occurrence of actionable gene fusions and microsatellite instability-high (MSI-H) in 20296 solid tumors: A pan-cancer analysis
Presenter: Tao Fu
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
LBA36 - Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
Presenter: Ana Oaknin
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast